Clinical Diagnostic Test Validated for Bacterial Vaginosis
By LabMedica International staff writers Posted on 09 Aug 2012 |
A clinical study supports validation of a new diagnostic test for bacterial vaginosis (BV).
Laboratory Corporation of America Holdings (LabCorp; Burlington, NC, USA) announced publication of the clinical study in the July 2012 Journal of Clinical Microbiology. A total of 402 women were enrolled in the study between April and October 2011. The studies were completed under institutional review board (IRB) approval in collaboration with the Department of Medicine, University of Alabama at Birmingham School of Medicine (UAB; Birmingham, AL, USA).
During the study, quantitative polymerase chain reaction (PCR) assays were developed for 4 organisms reported previously to be indicators for the diagnosis of bacterial vaginosis (BV) and a single organism that had been implicated as a negative indicator for BV. The new test, which is called Bacterial Vaginosis, is currently available as part of the NuSwabsm series of tests. LabCorp introduced NuSwab in 2011 as a single collection device that improves the convenience and efficacy of sample collection for clinically validated test profiles for targeted women's health clinical conditions.
"Bacterial vaginosis is a common condition, but physicians have limited tools to diagnose it properly," said Dr. Mark Brecher, LabCorp's CMO. "This test will help physicians diagnose BV with more specificity and provide better care. Patients are seeing demonstrable benefits from the NuSwab tests, and we will continue to enhance our NuSwab offerings to support better patient care."
The enhancement to LabCorp's test menu is an adjunct to its women's health test options, which include tests that focus on both screening and diagnosis of disease.
In addition to its women's health services, LabCorp offers a comprehensive menu of individual tests and test combinations to address specific patient needs.
Related Links:
LabCorp
Department of Medicine, University of Alabama at Birmingham School of Medicine
Laboratory Corporation of America Holdings (LabCorp; Burlington, NC, USA) announced publication of the clinical study in the July 2012 Journal of Clinical Microbiology. A total of 402 women were enrolled in the study between April and October 2011. The studies were completed under institutional review board (IRB) approval in collaboration with the Department of Medicine, University of Alabama at Birmingham School of Medicine (UAB; Birmingham, AL, USA).
During the study, quantitative polymerase chain reaction (PCR) assays were developed for 4 organisms reported previously to be indicators for the diagnosis of bacterial vaginosis (BV) and a single organism that had been implicated as a negative indicator for BV. The new test, which is called Bacterial Vaginosis, is currently available as part of the NuSwabsm series of tests. LabCorp introduced NuSwab in 2011 as a single collection device that improves the convenience and efficacy of sample collection for clinically validated test profiles for targeted women's health clinical conditions.
"Bacterial vaginosis is a common condition, but physicians have limited tools to diagnose it properly," said Dr. Mark Brecher, LabCorp's CMO. "This test will help physicians diagnose BV with more specificity and provide better care. Patients are seeing demonstrable benefits from the NuSwab tests, and we will continue to enhance our NuSwab offerings to support better patient care."
The enhancement to LabCorp's test menu is an adjunct to its women's health test options, which include tests that focus on both screening and diagnosis of disease.
In addition to its women's health services, LabCorp offers a comprehensive menu of individual tests and test combinations to address specific patient needs.
Related Links:
LabCorp
Department of Medicine, University of Alabama at Birmingham School of Medicine
Latest Microbiology News
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA
- Rapid Sepsis Test Delivers Two Days Faster Results
- Portable Rapid PCR Diagnostic to Detect Gonorrhea and Antibiotic Susceptibility